巴曲酶治疗老年突发性耳聋的临床观察

发布时间：2018-06-22 06:08

本文选题：老年突发性耳聋 + 巴曲酶　；参考：《中国药房》2017年12期

【摘要】：目的:观察巴曲酶治疗老年突发性耳聋的疗效和安全性。方法:102例老年突发性耳聋患者随机分为对照组(51例)和观察组(51例)。对照组患者给予银杏叶提取物注射液105 mg,静脉滴注+地塞米松磷酸钠注射液30 mg,静脉滴注+甲磺酸倍他司汀片6 mg,口服等常规治疗;观察组患者在对照组治疗的基础上给予巴曲酶注射液10 BU,加入0.9%氯化钠注射液100 m L中,静脉滴注,1 h内滴注完,后隔天给予5 BU,加入0.9%氯化钠注射液100 m L中,静脉滴注,1 h内滴注完。两组均连用10 d。观察两组患者的临床疗效,听力恢复时间、耳闷消失时间、眩晕消失时间和耳鸣消失时间,治疗前后纯音听阈值、血浆比黏度(ns)、高切变率下全血黏度(nbh)、低切变率下全血黏度(nbl)、血细胞比容(HCT)、红细胞沉降率(ESR)、血浆纤维蛋白原(Fb)、内皮素(ET)和一氧化氮(NO)水平及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,听力恢复时间、耳闷消失时间、眩晕消失时间和耳鸣消失时间均显著短于对照组,差异均有统计学意义(P0.05或P0.01)。治疗前,两组患者纯音听阈值、ns、nbh、nbl、HCT、ESR、Fb、ET和NO水平比较,差异均无统计学意义(P0.05)。治疗后,两组患者纯音听阈值、ns、nbh、nbl、HCT、ESR、Fb和ET水平均显著低于同组治疗前,且观察组显著低于对照组;两组患者NO水平均显著高于同组治疗前,且观察组显著高于对照组,差异均有统计学意义(P0.01)。两组患者治疗期间均未见明显不良反应发生。结论:在常规治疗的基础上,巴曲酶治疗老年突发性耳聋疗效显著,可改善症状,促进局部血流动力学恢复,改善内耳微循环障碍,且安全性较好。
[Abstract]:Objective: to observe the efficacy and safety of batroxobin in the treatment of senile sudden deafness. Methods 102 elderly patients with sudden deafness were randomly divided into control group (51 cases) and observation group (51 cases). Patients in the control group were treated with Ginkgo biloba extract injection 105 mg, dexamethasone sodium phosphate injection 30 mg, and betastine mesylate tablet 6 mg orally. The patients in the observation group were given batroxobin injection 10BU on the basis of treatment in the control group, adding 0.9% sodium chloride injection 100ml, intravenous drip was completed within 1 hour, the following day was given 5BU, and 0.9% sodium chloride injection 100ml was added. Intravenous drip was completed within 1 hour. Both groups were treated for 10 days. The clinical effect, hearing recovery time, ear stuffy disappearance time, vertigo disappearance time and tinnitus disappearance time were observed, and the threshold of pure tone audition before and after treatment were observed. Blood cell volume (HCT), erythrocyte sedimentation rate (ESR), plasma fibrinogen (FB), endothelin (et) and nitric oxide (no) levels and adverse reactions of whole blood viscosity (nbl), at low shear rate of whole blood viscosity (nbh),) at high shear rate of plasma specific viscosity (ns), erythrocyte sedimentation rate (ESR), plasma fibrinogen (FB), endothelin (et) and nitric oxide (no) were observed. Results: the total effective rate of the observation group was significantly higher than that of the control group. The time of hearing recovery, ear stuffy disappearance, vertigo disappearance and tinnitus disappearance were significantly shorter in the observation group than in the control group (P0.05 or P0.01). Before treatment, there was no significant difference in the levels of et and no between the two groups (P 0.05). After treatment, the threshold of pure tone audition and the levels of ESRFb and et in the two groups were significantly lower than those before the treatment in the same group, and the levels of no in the observation group were significantly higher than those in the control group, and the levels of no in the observation group were significantly higher than those in the control group, and the level of no in the observation group was significantly higher than that in the control group. The difference was statistically significant (P0.01). No significant adverse reactions occurred during treatment in both groups. Conclusion: on the basis of routine treatment, Batroxobin is effective in treating senile sudden deafness. It can improve symptoms, promote regional hemodynamic recovery and improve the disturbance of inner ear microcirculation.
【作者单位】：南阳市中心医院/郑州大学附属南阳医院耳鼻喉科一病区
【分类号】：R764.437

【参考文献】